Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04925557 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis
A Phase 2 study, sponsored by State University of New York at Buffalo.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04925557: Clinical Trial Phase 2 study, sponsored by State University of New York at Buffalo.
NCT04925557 is a Phase 2 study that was terminated before completion, run by State University of New York at Buffalo. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04925557, a Phase 2 study, was terminated before completion, sponsored by State University of New York at Buffalo.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
To assess the efficacy of Mayzent on microglia pathology in patients with active SPMS, as compared to the active control group of MS patients treated with the Ocrevus, as measured by changes in microglial activation in the lesional and non-lesional NAWM and NAGM and in the peri-plaque area of chronic lesions in the brain.
Primary Outcome
Change from baseline in PET activation of PBR06 in lesional and non-lesional NAWM and NAGM in the brain of the patients under treatment with Mayzent when 100% of patients reach 12 months;
Interventions
- DRUG Mayzent
- DRUG Ocrevus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-11-13 |
| Est. Completion | 2023-08-05 |
| Phase | Phase 2 |
Why NCT04925557 stopped before completion
NCT04925557 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Mayzent is the first listed.
NCT04925557 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04925557 about?
NCT04925557 is a clinical study titled "Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis". To assess the efficacy of Mayzent on microglia pathology in patients with active SPMS, as compared to the active control group of MS patients treated with the Ocrevus, as measured by changes in microglial activation in the lesional and non-lesional NAWM and NAGM and in the peri-plaque area of chroni...
What is the current status of trial NCT04925557?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2021-11-13. Estimated completion is 2023-08-05.
What interventions are being tested in trial NCT04925557?
The interventions under investigation include: Mayzent (DRUG), Ocrevus (DRUG).
Who is sponsoring clinical trial NCT04925557?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04925557's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI